Travere Therapeutics

TVTX

Market cap $3.77B

Travere Therapeutics is rated a BUY following Filspari's landmark FDA approval for FSGS, making it the only approved therapy for this indication. TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs.

A director of Travere Therapeutics reported selling 8,000 shares in the open market on April 14, 2026, generating a transaction value of about $329,000. The sale represented 12.21% of Gary A.

Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point of 42.13.

Travere Therapeutics secured full FDA approval for Filspari in FSGS, expanding its rare kidney disease franchise and driving a 37% stock surge. The FSGS approval increases TVTX's U.S. addressable market by 30,000 patients, supporting a multi-year revenue and earnings inflection not yet fully reflected in estimates. Filspari's unique, non-immunosuppressive mechanism and first-mover status in FSGS position TVTX for premium pricing and significant volume-driven revenue growth.

Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,420 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.

Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare kidney, liver, and metabolic diseases.

Travere Therapeutics stock jumped early Tuesday after the FDA approved Filspari for a new kidney disease.

Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript